AbbVie Scores HCV First Under UK’s Early Access Scheme

AbbVie’s investigational hepatitis C treatment has become the latest therapy to get the green light under the UK’s early access to medicines scheme. The scheme enables patients to access the treatment ahead of it receiving an EU marketing authorization.